SAN DIEGO, November 04, 2021 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (BNGO), developer of Saphyr® which uses optical genome mapping (OGM) for the detection and analysis of structural variants (SV), today announced that two former Illumina executives, Stephanie Hoyle and Alex Helm, have joined the company as vice-presidents of corporate marketing and strategic product marketing, respectively. Together, they bring 22 years of genomics experience and 36 years of marketing experience.
At Bionano, Stéphanie will oversee the company’s global marketing and branding strategy. During her tenure at Illumina, she held similar positions and was instrumental in developing the branding and marketing strategy of the Reproductive Health and Genetics business unit. . After leaving Illumina, Stéphanie founded the Hoyle Marketing Group. She has worked with numerous life science companies on branding and marketing, including BioLegend, ChromaCode, CodexDNA, Fortis Life Sciences, Rady’s Children’s Institute for Genomic Medicine and Verogen.
Alex will be responsible for developing the long-term global product roadmap and portfolio strategy for Bionano’s suite of products and service solutions to influence the company’s annual strategic planning process. Previously, he was Regional Marketing Director for the Americas at Illumina and responsible for clinical segments including oncology, genetic and infectious disease testing, and reproductive health. As Global Head of Illumina’s Reproductive and Genetic Health business unit, Alex oversaw a critical product launch for the IVD-labeled VeriSeq NIPT solution, which significantly expanded access to safer prenatal testing for families. of the whole world.
“I am delighted that Stephanie and Alex have joined our team to lead our brand evolution and strategic product marketing planning,” said Erik Holmlin, PhD, CEO of Bionano Genomics. “By providing better product solutions to our customers, our goal is to improve human health and ultimately create better patient outcomes. “
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to difficult questions in biology and medicine. The Company’s mission is to transform the way the world views the genome through optical genome mapping (GMO) solutions, diagnostic services and software. The Company offers GMO solutions for applications in basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic tests for patients with clinical presentations consistent with autism spectrum disorders and other neurodevelopmental disorders. Through its BioDiscovery business, the Company also offers an industry-leading, platform-independent software solution that integrates next-generation DNA sequencing and microarray data designed to provide analysis, visualization, interpretation and analysis. ratio of copy number variants, single nucleotide variants and absence. of heterozygosity across the genome in a consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com
Bionano Genomics forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “plan”, “anticipate”, “estimate” , “Intend to” and similar expressions (as well as other words or phrases referring to future events, conditions or circumstances) convey the uncertainty of future events or results and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analysis or current expectations regarding, among others: the impact of the expansion of our marketing leadership team, including our expectations regarding the growth of Saphyr® and our ability to strengthen the customer experience globally. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that could cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; our recruiting efforts may not achieve the desired results; changes in our strategic and business plans; our ability to secure sufficient funding to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; the loss of key members of management and our sales team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2020 and in other documents subsequently filed by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of that date. We assume no obligation to publicly update any forward-looking statements, whether as a result of receipt of new information, the occurrence of future events, or otherwise.
Company details :
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
+1 (858) 366-3243
+1 (503) 799-7520